newsfilter
← Latest News
ACCESS Newswire·

NLS Pharmaceutics Announces FDA Acceptance of IND Application to Initiate Clinical Trials with Quilience(R) (mazindol ER) to Treat Narcolepsy

Planned Phase 2a clinical trial anticipated to commence in August 2021 STANS, SWITZERLAND / ACCESSWIRE / July 15, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused o